Hefty drug price increases have been an outrage-provoking subject for politicians, the public and pharmacy benefits managers all year long. But another group besides drugmakers has been benefiting from them: dealmakers.
Private companies have been taking advantage of climbing prices by buying older drugs on the cheap, hiking their stickers, and reselling them, Bloomberg reports, citing data from software company Connecture.
Take Actimmune, which a private equity outfit bought from Genentech in 2012 for $55 million, for example. Its price climbed by 434% in two years before Horizon Pharma grabbed it for $660 million.
Then there’s Novartis’ cold-sore cream Denavir, whose price leapt 372% over two transactions aided by private equity. And the list goes on and on.
Of course, drug flippers aren’t the only price-hike offenders. Plenty of drugmakers have notched sizable increases on meds that haven’t changed hands at all, and one need only look at key Mylan blockbuster EpiPen, one of Congress’ most recent price-hike scapegoats, to see it.
Instead, they’re “taking advantage of a dysfunctional market,” Stephen Schondelmeyer, a professor of pharmaceutical economics at the University of Minnesota, told Bloomberg.
One reason? There’s “very little risk” in picking up drugs, ZS Associates’ managing principal Pratap Khedkar told the news service. Other private-equity firms see a relatively quick payout on the horizon.
Of course, as pharma’s drug-pricing scandal rages on, there’s more and more possibility of winding up in an unwelcome spotlight, as Concordia Pharmaceuticals knows. The company–one of several in the specialty pharma space that’s been hit especially hard by the crackdown–recently raised prices on two meds purchased from a PE outfit that had already made its own increases.
That price lift didn’t go unnoticed by CVS Health, which kicked the drugs–Nilandron and Dutoprol, up 989% and 1,057% respectively since 2013, off its formulary.
A lot of jacked-up drugs still do fly under the radar, though, John Bennett, CEO of nonprofit insurer Capital District Physicians’ Health Plan, told Bloomberg. So, while drug flippers may not be the only group contributing to skyrocketing drug costs, “the bottom line is it all adds up,” he said.
By Carly Helfand
Source: Fierce Pharma
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.